HOME
FAIRE UN DON
EN FR
Current language is French. Click to change language
EN FR

Branche Surveillance du cancer (CSU)

Cancer Surveillance Branch (CSU)

Publications

Publications recentes: 2025-2022

Visualisez les publications recentes

 

  1. Alessy SA, Morgan E, Al-Zahrani AS, Zahwe M, Fouad H, Bray F, et al. (2025). Burden of five major types of gastrointestinal cancer in the Eastern Mediterranean Region. BMJ Open Gastroenterol. 12(1). https://doi.org/10.1136/bmjgast-2024-001577 PMID: 39971587
  2. Bajwa A, Chidebe RCW, Adams T, Funston G, Soerjomataram I, Cohen R, et al. (2025). Challenges and opportunities in ovarian cancer care: A qualitative study of clinician perspectives from 24 low- and middle-income countries. J Cancer Policy. 44: 100582. https://doi.org/10.1016/j.jcpo.2025.100582 PMID: 40203992
  3. Best AF, Filho AM, Rosenberg PS (2025). Forecasting cancer incidence and prevalence using age-period-cohort and survivorship models: a practical, flexible, and interpretable framework. Front Oncol. 15: 1484896. https://doi.org/10.3389/fonc.2025.1484896 PMID: 40224176
  4. Bray F, Laversanne MO (2025). Stat Bite: recent trends in colon cancer incidence at ages 25-49 vs 50-74 in 50 countries. J Natl Cancer Inst. 117(10): 2146-2147. https://doi.org/10.1093/jnci/djaf223 PMID: 41062101
  5. Bray FI, Laversanne M, Colombet MF (2025). Stat Bite: National or subnational coverage of population-based cancer registries included in Cancer Incidence in Five Continents, Volume XII. J Natl Cancer Inst. 117(2): 383-384. https://doi.org/10.1093/jnci/djae303 PMID: 40748550
  6. Bray FI, Vignat JA (2025). Stat Bite: Variations in nasopharyngeal cancer incidence rates according to registries included in Cancer Incidence in Five Continents, Volume XII. J Natl Cancer Inst. 117(4): 816-817. https://doi.org/10.1093/jnci/djaf029 PMID: 40748659
  7. da Cunha AR, Rumgay H, Vignat J, Laversanne M, Colombet M, Curado MP, et al. (2025). Global burden and international trends of laryngeal cancer incidence: A population-based study of recorded data and national estimates. Cancer Epidemiol. 99: 102935. https://doi.org/10.1016/j.canep.2025.102935 PMID: 40997398
  8. Dal Maso L, Vaccarella S, Franceschi S (2025). Trends in thyroid cancer incidence and overdiagnosis in the USA. Lancet Diabetes Endocrinol. 13(3): 167-169. https://doi.org/10.1016/S2213-8587(24)00343-7 PMID: 39922211
  9. Daltveit DS, Morgan E, Colombet M, Steliarova-Foucher E, Bendahhou K, Marcos-Gragera R, et al. (2025). Global patterns of leukemia by subtype, age, and sex in 185 countries in 2022. Leukemia. 39(2): 412-419. https://doi.org/10.1038/s41375-024-02452-y PMID: 39567675
  10. de Heus E, Duijts SFA, van der Zwan JM, van Herpen CML, Merkx MAW, Rutherford MJ, et al. (2025). Measuring healthy life expectancy and determinants of poor perceived health: A population-based study among a subset of rare and common cancer survivors. Cancer Epidemiol. 94: 102706. https://doi.org/10.1016/j.canep.2024.102706 PMID: 39579642
  11. de Vries E, Arias-Ortiz N, Pineros M (2025). Commentary to Oliveros et al., Cancer Epidemiol 2025;96:102784. Cancer Epidemiol. 96: 102813. https://doi.org/10.1016/j.canep.2025.102813 PMID: 40184951
  12. Dee EC, Laversanne M, Bhoo-Pathy N, Ho FDV, Feliciano EJG, Eala MAB, et al. (2025). Cancer incidence and mortality estimates in 2022 in southeast Asia: a comparative analysis. Lancet Oncol. 26(4): 516-528. https://doi.org/10.1016/S1470-2045(25)00017-8 PMID: 40024257
  13. Ebrahimi E, Sangphukieo A, Park HA, Gaborieau V, Ferreiro-Iglesias A, Diergaarde B, et al. (2025). Cross-ancestral GWAS identifies 29 variants across head and neck cancer subsites. Nat Commun. 16(1): 8787. https://doi.org/10.1038/s41467-025-63842-z PMID: 41038832
  14. Eslahi M, Pizzato M, Heikkinen S, Martinsen JI, Lynge E, Hansen J, et al. (2025). Socioeconomic position and risk of cervical cancer in the Nordic countries: Results from the Nordic Occupational Cancer Study. Int J Cancer. 157(1): 95-102. https://doi.org/10.1002/ijc.35349 PMID: 40079673
  15. Fedoriw Y, Silva O, Znaor A, Macintyre E (2025). Global view of haematolymphoid tumor classifications and their application in low- and middle-income countries. Histopathology. 86(1): 6-16. https://doi.org/10.1111/his.15340 PMID: 39420576
  16. Filho AM, Laversanne M, Ferlay J, Colombet M, Pineros M, Znaor A, et al. (2025). The GLOBOCAN 2022 cancer estimates: Data sources, methods, and a snapshot of the cancer burden worldwide. Int J Cancer. 156(7): 1336-1346. https://doi.org/10.1002/ijc.35278 PMID: 39688499
  17. Filho AM, Znaor A, Sunguc C, Zahwe M, Marcos-Gragera R, Figueroa JD, et al. (2025). Cancers of the brain and central nervous system: global patterns and trends in incidence. J Neurooncol. 172(3): 567-578. https://doi.org/10.1007/s11060-025-04944-y PMID: 39883354
  18. Forjaz G, Kohler B, Coleman MP, Steliarova-Foucher E, Negoita S, Guidry Auvil JM, et al. (2025). Making the case for an International Childhood Cancer Data Partnership. J Natl Cancer Inst. 117(8): 1539-1546. https://doi.org/10.1093/jnci/djaf003 PMID: 39799506
  19. Garton EM, Allman G, Bae HS, Duncan K, Fadhil I, Hammad N, et al. (2025). A proposed framework for monitoring and evaluating progress at the intersection of women, power, and cancer. Lancet. 405(10490): 1713-1716. https://doi.org/10.1016/S0140-6736(25)00511-2 PMID: 40250454
  20. Hermansen M, Hjelmborg J, Thinggaard M, Znaor A, Skakkebaek NE, Lindahl-Jacobsen R (2025). Smoking and testicular cancer: A Danish nationwide cohort study. Cancer Epidemiol. 95: 102746. https://doi.org/10.1016/j.canep.2025.102746 PMID: 39813870
  21. Huang Y, Georges D, Rumgay H, Soerjomataram I, Clifford GM (2025). Global burden of cancer attributable to HIV: a worldwide incidence analysis. Lancet Glob Health. 13(9): e1525-e1532. https://doi.org/10.1016/S2214-109X(25)00264-5 PMID: 40845879
  22. Kim J, Harper A, McCormack V, Sung H, Houssami N, Morgan E, et al. (2025). Global patterns and trends in breast cancer incidence and mortality across 185 countries. Nat Med. 31(4): 1154-1162. https://doi.org/10.1038/s41591-025-03502-3 PMID: 39994475
  23. Langselius O, Rumgay H, de Vries E, Whiteman DC, Jemal A, Parkin DM, et al. (2025). Global burden of cutaneous melanoma incidence attributable to ultraviolet radiation in 2022. Int J Cancer. 157(6): 1110-1119. https://doi.org/10.1002/ijc.35463 PMID: 40421619
  24. Larcher A, Campi R, Bex A, Bray F, Bukavina L, Jonasch E, et al. (2025). Epidemiology of Renal Cancer: Incidence, Mortality, Survival, Genetic Predisposition, and Risk Factors. Eur Urol. 88(4): 341-358. https://doi.org/10.1016/j.eururo.2025.06.005 PMID: 40750496
  25. Li Y, Tian J, You Y, Ru C, Zheng R, Wang S, et al. (2025). Global variations and socioeconomic inequalities in lifetime risk of lip, oral cavity, and pharyngeal cancer: a population-based systematic analysis of GLOBOCAN 2022. Int J Surg. 111(6): 3698-3709. https://doi.org/10.1097/JS9.0000000000002408 PMID: 40277389
  26. Luo G, Zhang Y, Rumgay H, Morgan E, Langselius O, Vignat J, et al. (2025). Estimated worldwide variation and trends in incidence of lung cancer by histological subtype in 2022 and over time: a population-based study. Lancet Respir Med. 13(4): 348-363. https://doi.org/10.1016/S2213-2600(24)00428-4 PMID: 39914442
  27. Mafra A, Laversanne M, Marcos-Gragera R, Chaves HVS, McShane C, Bray F, et al. (2025). The global multiple myeloma incidence and mortality burden in 2022 and predictions for 2045. J Natl Cancer Inst. 117(5): 907-914. https://doi.org/10.1093/jnci/djae321 PMID: 39658225
  28. Mallon B, Dial C, Akonde FB, Ahouidi MJD, Diouf N, Anne M, et al. (2025). The path towards a population-based childhood cancer registry in the region of Dakar in Senegal: A feasibility study of the Franco-African Paediatric Oncology Group (GFAOP). Ejc Paediatric Oncology. 6: 100420. https://doi.org/10.1016/j.ejcped.2025.100420
  29. Park JY, Georges D, Alberts CJ, Bray F, Clifford G, Baussano I (2025). Global lifetime estimates of expected and preventable gastric cancers across 185 countries. Nat Med. 31(9): 3020-3027. https://doi.org/10.1038/s41591-025-03793-6 PMID: 40624406
  30. Pena-Torres E, de Vries E, de Camargo Cancela M, Pineros-Petersen M (2025). Use of population-based cancer registries for cancer surveillance and control in Latin America. Cancer Epidemiol. 99: 102914. https://doi.org/10.1016/j.canep.2025.102914 PMID: 40934652
  31. Pineros M, Morgan E, Brierley J (2025). Reporting stage at diagnosis: Opportunities for improvement. Cancer Epidemiol. 97: 102819. https://doi.org/10.1016/j.canep.2025.102819 PMID: 40252288
  32. Pineros M, Vignat J, Colombet M, Laversanne M, Ferreccio C, Heise K, et al. (2025). Global variations in gallbladder cancer incidence: What do recorded data and national estimates tell us? Int J Cancer. 156(7): 1358-1368. https://doi.org/10.1002/ijc.35232 PMID: 39580808
  33. Pizzato M, McCormack V, Dossus L, Al-Alem U, Delpierre C, Lamy S, et al. (2025). Education level and risk of breast cancer by tumor subtype in the EPIC cohort. Int J Cancer. 157(4): 672-686. https://doi.org/10.1002/ijc.35413 PMID: 40170258
  34. Radhakrishnan V, Jothi A, Mary R, Veeraiah S, Sudhakar R, Selvam P, et al. (2025). Assessment of Barriers and Enablers for Implementing a Population-Based Childhood Cancer Registry in Chennai, India. Pediatr Blood Cancer. 72(3): e31500. https://doi.org/10.1002/pbc.31500 PMID: 39739444
  35. Rey Brandariz J, Perez-Rios M, Ruano-Ravina A, Soerjomataram I (2025). Reflections on the tobacco-free generation: methodological challenges and global implications – Authors’ reply. Lancet Public Health. 10(2): e83. https://doi.org/10.1016/S2468-2667(25)00008-8 PMID: 39909695
  36. Sawant P, Saoba S, Kadam P, Gupta D, Ponnada AK, Khanna D, et al. (2025). The Nirmiti application: An innovative tool for extending CanReg5 analyses to cancer mortality and paediatric cancer. Int J Cancer. 157(1): 161-169. https://doi.org/10.1002/ijc.35420 PMID: 40156432
  37. Schafer EJ, Laversanne M, Sung H, Soerjomataram I, Briganti A, Dahut W, et al. (2025). Recent Patterns and Trends in Global Prostate Cancer Incidence and Mortality: An Update. Eur Urol. 87(3): 302-313. https://doi.org/10.1016/j.eururo.2024.11.013 PMID: 39668103
  38. Shah R, Battisti NML, Brain E, Gnangnon FHR, Kanesvaran R, Mohile S, et al. (2025). Updated cancer burden in oldest old: A population-based study using 2022 Globocan estimates. Cancer Epidemiol. 95: 102716. https://doi.org/10.1016/j.canep.2024.102716 PMID: 39603975
  39. Shah R, Hanna NM, Loo CE, David M, Mafra A, Fink H, et al. (2025). The global impact of the COVID-19 pandemic on delays and disruptions in cancer care services: a systematic review and meta-analysis. Nat Cancer. 6(1): 194-204. https://doi.org/10.1038/s43018-024-00880-4 PMID: 39747650
  40. Soerjomataram I, Bardot A, Bray FM (2025). Stat Bite: Surviving or dying from colon cancer or other causes 5 years after diagnosis, Australia 2010-2014, females. J Natl Cancer Inst. 117(5): 1090-1091. https://doi.org/10.1093/jnci/djaf045 PMID: 40748608
  41. Soerjomataram I, Bray F (2025). Stat Bite: Infectious agents as global causes of cancer in 2020. Jnci-Journal of the National Cancer Institute. 117(6): 1291-1292. https://doi.org/10.1093/jnci/djaf091
  42. Soerjomataram I, Bray F (2025). Stat Bite: Proportion of all cancers eligible for screening in 2022. JNCI: Journal of the National Cancer Institute. 117(8): 1758-1759. https://doi.org/10.1093/jnci/djaf147
  43. Stoer NC, Vangen S, Singh D, Fortner RT, Hofvind S, Ursin G, et al. (2025). Correction: Menopausal hormone therapy and breast cancer risk: a population-based cohort study of 1.3 million women in Norway. Br J Cancer. 133(6): 910-911. https://doi.org/10.1038/s41416-025-03038-w PMID: 40835748
  44. Sung H, Siegel RL, Laversanne M, Jiang C, Morgan E, Zahwe M, et al. (2025). Colorectal cancer incidence trends in younger versus older adults: an analysis of population-based cancer registry data. Lancet Oncol. 26(1): 51-63. https://doi.org/10.1016/S1470-2045(24)00600-4 PMID: 39674189
  45. Van Eycken LJ, Giannopoulos E, Tittenbrun Z, Pineros M, Mery L, Rahal R, et al. (2025). Future of population-based cancer registries: A global perspective-A survey of population-based cancer registries. Int J Cancer. 157(8): 1566-1576. https://doi.org/10.1002/ijc.35516 PMID: 40490886
  46. Warnakulasuriya S, Filho AMM (2025). Oral Cancer in the South and South-East Asia Region, 2022: Incidence and Mortality. Oral Dis. 31(5): 1398-1405. https://doi.org/10.1111/odi.15369 PMID: 40364456
  47. Weber A, Bray F, Arvai M, Hilbert L, Kelemen D, Nagy P, et al. (2025). Half a century of cancer transition in Hungary: A visualization and assessment of mortality dynamics in the Lexis diagram, 1970-2020. Cancer Epidemiol. 99: 102925. https://doi.org/10.1016/j.canep.2025.102925 PMID: 40939417
  48. Zahwe M, Bendahhou K, Eser S, Mukherji D, Fouad H, Fadhil I, et al. (2025). Current and future burden of female breast cancer in the Middle East and North Africa region using estimates from GLOBOCAN 2022. Int J Cancer. 156(12): 2320-2329. https://doi.org/10.1002/ijc.35325 PMID: 39791948
  49. Znaor A, Fouad H, Zahwe M, Eser S, Fadhil I, Soerjomataram I, et al. (2025). Cancer surveillance in the Eastern Mediterranean region: a 10-year International Agency for Research on Cancer-WHO Regional Office for the Eastern Mediterranean collaboration. Lancet Oncol. 26(3): e131-e139. https://doi.org/10.1016/S1470-2045(24)00624-7 PMID: 40049204
  50. Abu Awwad D, Shafiq J, Delaney GP, Anacak Y, Bray F, Flores JA, et al. (2024). Current and projected gaps in the availability of radiotherapy in the Asia-Pacific region: a country income-group analysis. Lancet Oncol. 25(2): 225-234. https://doi.org/10.1016/S1470-2045(23)00619-8 PMID: 38301690
  51. Alessy SA, Alqahtani SA, Vignat J, Abuhmaidan A, Basmi AEL, Al Lawati N, et al. (2024). The current and future cancer burden in the Gulf Cooperation Council (GCC) countries. Cancer Med. 13(17): e70141. https://doi.org/10.1002/cam4.70141 PMID: 39279725
  52. Benitez Fuentes JD, Morgan E, de Luna Aguilar A, Mafra A, Shah R, Giusti F, et al. (2024). Global Stage Distribution of Breast Cancer at Diagnosis: A Systematic Review and Meta-Analysis. JAMA Oncol. 10(1): 71-78. https://doi.org/10.1001/jamaoncol.2023.4837 PMID: 37943547
  53. Benitez Fuentes JD, Morgan E, Soerjomataram I (2024). Clarification Regarding Breast Cancer Stage in France-Reply. JAMA Oncol. 10(6): 832-833. https://doi.org/10.1001/jamaoncol.2024.0671 PMID: 38662350
  54. Bray F (2024). Cancer trends in the UK. BMJ. 384: q504. https://doi.org/10.1136/bmj.q504 PMID: 38479756
  55. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. (2024). Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 74(3): 229-263. https://doi.org/10.3322/caac.21834 PMID: 38572751
  56. Businge L, Hagenimana M, Motlhale M, Bardot A, Liu B, Anastos K, et al. (2024). Stage at diagnosis and survival by stage for the leading childhood cancers in Rwanda. Pediatr Blood Cancer. 71(7): e31020. https://doi.org/10.1002/pbc.31020 PMID: 38668553
  57. Corredor C, Pineros M, Wiesner C, de Vries E (2024). Using administrative registries as a source for population-based cancer incidence and mortality. BMC Cancer. 24(1): 232. https://doi.org/10.1186/s12885-023-11754-w PMID: 38373947
  58. de Paula Silva N, Colombet M, Moreno F, Erdmann F, Dolya A, Pineros M, et al. (2024). Incidence of childhood cancer in Latin America and the Caribbean: coverage, patterns, and time trends. Rev Panam Salud Publica. 48: e11. https://doi.org/10.26633/RPSP.2024.11 PMID: 38410357
  59. de Paula Silva N, Gini A, Dolya A, Colombet M, Soerjomataram I, Youlden D, et al. (2024). Prevalence of childhood cancer survivors in Europe: a scoping review. EJC Paediatr Oncol. 3. https://doi.org/10.1016/j.ejcped.2024.100155 PMID: 38915419
  60. Fantin R, Sierra MS, Vaccarella S, Herrero R, Barboza-Solis C (2024). Social gradient and rural-urban disparities in cancer mortality in Costa Rica. Cancer Epidemiol. 91: 102604. https://doi.org/10.1016/j.canep.2024.102604 PMID: 38941875
  61. Ghasemi-Kebria F, Fazel A, Semnani S, Etemadi A, Naeimi-Tabiei M, Hasanpour-Heidari S, et al. (2024). Breast cancer incidence trends in Golestan, Iran: An age-period-cohort analysis by ethnic region, 2004-2018. Cancer Epidemiol. 89: 102525. https://doi.org/10.1016/j.canep.2024.102525 PMID: 38228040
  62. Gizaw M, Parkin DM, Stoter O, Bukirwa P, Seife E, Chesumbai G, et al. (2024). Ovarian cancer survival in sub-Saharan Africa by human development index and histological subtypes: A population-based registry study. Int J Cancer. 154(11): 1911-1919. https://doi.org/10.1002/ijc.34877 PMID: 38339849
  63. Guimaraes Ribeiro A, Ferlay J, Vaccarella S, Dias de Oliveira Latorre MDR, Tavares Guerreiro Fregnani JH, Bray F (2024). Ethnic disparities in cancer mortality in the capital and northeast of the State of Sao Paulo, Brazil 2001-17. Cancer Causes Control. 35(3): 523-529. https://doi.org/10.1007/s10552-023-01812-w PMID: 37917366
  64. Hagenimana M, Motlhale M, Parkin DM, Businge L, Bardot A, Liu B, et al. (2024). Stage at diagnosis and survival among adult patients with cancer in Rwanda: A population-based study. Int J Cancer. 155(6): 988-995. https://doi.org/10.1002/ijc.34969 PMID: 38888375
  65. Islami F, Marlow EC, Thomson B, McCullough ML, Rumgay H, Gapstur SM, et al. (2024). Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States, 2019. CA Cancer J Clin. 74(5): 405-432. https://doi.org/10.3322/caac.21858 PMID: 38990124
  66. James ND, Tannock I, N’Dow J, Feng F, Gillessen S, Ali SA, et al. (2024). The Lancet Commission on prostate cancer: planning for the surge in cases. Lancet. 403(10437): 1683-1722. https://doi.org/10.1016/S0140-6736(24)00651-2 PMID: 38583453
  67. Joko-Fru WY, Bardot A, Bukirwa P, Amidou S, N’da G, Woldetsadik E, et al. (2024). Cancer survival in sub-Saharan Africa (SURVCAN-3): a population-based study. Lancet Glob Health. 12(6): e947-e959. https://doi.org/10.1016/S2214-109X(24)00130-X PMID: 38762297
  68. Kenessey I, Parrag P, Dobozi M, Szatmari I, Weber A, Nagy P, et al. (2024). The epidemiology of lung cancer in Hungary based on the characteristics of patients diagnosed in 2018. Sci Rep. 14(1): 20064. https://doi.org/10.1038/s41598-024-70143-w PMID: 39209889
  69. Koyanagi YN, Nakatochi M, Namba S, Oze I, Charvat H, Narita A, et al. (2024). Genetic architecture of alcohol consumption identified by a genotype-stratified GWAS and impact on esophageal cancer risk in Japanese people. Sci Adv. 10(4): eade2780. https://doi.org/10.1126/sciadv.ade2780 PMID: 38277453
  70. Kusters JMA, Diergaarde B, Ness A, Schim van der Loeff MF, Heijne JCM, Schroeder L, et al. (2024). Diagnostic accuracy of HPV16 early antigen serology for HPV-driven oropharyngeal cancer is independent of age and sex. Int J Cancer. 154(2): 389-402. https://doi.org/10.1002/ijc.34710 PMID: 37694289
  71. Li M, Dal Maso L, Pizzato M, Vaccarella S (2024). Evolving epidemiological patterns of thyroid cancer and estimates of overdiagnosis in 2013-17 in 63 countries worldwide: a population-based study. Lancet Diabetes Endocrinol. 12(11): 824-836. https://doi.org/10.1016/S2213-8587(24)00223-7 PMID: 39389067
  72. Malagon T, Franco EL, Tejada R, Vaccarella S (2024). Epidemiology of HPV-associated cancers past, present and future: towards prevention and elimination. Nat Rev Clin Oncol. 21(7): 522-538. https://doi.org/10.1038/s41571-024-00904-z PMID: 38760499
  73. Moen L, Liu B, Bukirwa P, Chingonzoh T, Chokunonga E, Finesse A, et al. (2024). Trends in the incidence of colorectal cancer in sub-Saharan Africa: A population-based registry study. Int J Cancer. 155(4): 675-682. https://doi.org/10.1002/ijc.34942 PMID: 38568397
  74. Moreira DC, Znaor A, Santana VM, Dolya A, Fox Irwin L, Bhakta N, et al. (2024). Expanding the Global Capacity for Childhood Cancer Registration: The ChildGICR Masterclass. JCO Glob Oncol. 10: e2300334. https://doi.org/10.1200/GO.23.00334 PMID: 38905577
  75. Morgan E, O’Neill C, Bardot A, Walsh P, Woods RR, Gonsalves L, et al. (2024). Collecting Long-Term Outcomes in Population-Based Cancer Registry Data: The Case of Breast Cancer Recurrence. JCO Glob Oncol. 10: e2400249. https://doi.org/10.1200/GO-24-00249 PMID: 39481072
  76. Morgan E, O’Neill C, Shah R, Langselius O, Su Y, Frick C, et al. (2024). Metastatic recurrence in women diagnosed with non-metastatic breast cancer: a systematic review and meta-analysis. Breast Cancer Res. 26(1): 171. https://doi.org/10.1186/s13058-024-01881-y PMID: 39605105
  77. Murthy SS, Trapani D, Cao B, Bray F, Murthy S, Kingham TP, et al. (2024). Premature mortality trends in 183 countries by cancer type, sex, WHO region, and World Bank income level in 2000-19: a retrospective, cross-sectional, population-based study. Lancet Oncol. 25(8): 969-978. https://doi.org/10.1016/S1470-2045(24)00274-2 PMID: 38964357
  78. Poudel KK, Singh D, Sims DJ (2024). Gastric Cancer Survival and Its Predictors in Nepal. Asian Pac J Cancer Prev. 25(10): 3635-3642. https://doi.org/10.31557/APJCP.2024.25.10.3635 PMID: 39471031
  79. Rahman MS, Rahman MM, Acharya K, Haruyama R, Shah R, Matsuda T, et al. (2024). Disparities and Determinants of Testing for Early Detection of Cervical Cancer among Nepalese Women: Evidence from a Population-Based Survey. Cancer Epidemiol Biomarkers Prev. 33(8): 1046-1056. https://doi.org/10.1158/1055-9965.EPI-24-0037 PMID: 38820125
  80. Reid F, Adams T, Adel RS, Andrade CE, Bajwa A, Bambury IG, et al. (2024). The every woman study low- and middle-income countries edition protocol: A multi-country observational study to assess opportunities and challenges to improving survival and quality of life for women with ovarian cancer. PLoS One. 19(5): e0298154. https://doi.org/10.1371/journal.pone.0298154 PMID: 38809901
  81. Rey Brandariz J, Rumgay H, Ayo-Yusuf O, Edwards R, Islami F, Liu S, et al. (2024). Estimated impact of a tobacco-elimination strategy on lung-cancer mortality in 185 countries: a population-based birth-cohort simulation study. Lancet Public Health. 9(10): e745-e754. https://doi.org/10.1016/S2468-2667(24)00185-3 PMID: 39366730
  82. Ritter J, de Braganca J, Auste C, Mendez A, Cohen PD, Fajardo AF, et al. (2024). Novel Framework of Financial Hardship in Childhood Cancer: Incorporating Stakeholder Perspectives. JCO Glob Oncol. 10: e2400093. https://doi.org/10.1200/GO.24.00093 PMID: 39208390
  83. Rumgay H, Nethan ST, Shah R, Vignat J, Ayo-Yusuf O, Chaturvedi P, et al. (2024). Global burden of oral cancer in 2022 attributable to smokeless tobacco and areca nut consumption: a population attributable fraction analysis. Lancet Oncol. 25(11): 1413-1423. https://doi.org/10.1016/S1470-2045(24)00458-3 PMID: 39393386
  84. Shah R, Loo CE, Hanna NM, Hughes S, Mafra A, Fink H, et al. (2024). Global review of COVID-19 mitigation strategies and their impact on cancer service disruptions. J Cancer Policy. 41: 100486. https://doi.org/10.1016/j.jcpo.2024.100486 PMID: 38830535
  85. Smith CDL, McMahon AD, Lyall DM, Goulart M, Inman GJ, Ross A, et al. (2024). Development and external validation of a head and neck cancer risk prediction model. Head Neck. 46(9): 2261-2273. https://doi.org/10.1002/hed.27834 PMID: 38850089
  86. Sohi I, Rehm J, Saab M, Virmani L, Franklin A, Sanchez G, et al. (2024). Alcoholic beverage consumption and female breast cancer risk: A systematic review and meta-analysis of prospective cohort studies. Alcohol Clin Exp Res (Hoboken). 48(12): 2222-2241. https://doi.org/10.1111/acer.15493 PMID: 39581746
  87. Steinberg J, Hughes S, Hui H, Allsop MJ, Egger S, David M, et al. (2024). Risk of COVID-19 death for people with a pre-existing cancer diagnosis prior to COVID-19-vaccination: A systematic review and meta-analysis. Int J Cancer. 154(8): 1394-1412. https://doi.org/10.1002/ijc.34798 PMID: 38083979
  88. Stoer NC, Vangen S, Singh D, Fortner RT, Hofvind S, Ursin G, et al. (2024). Menopausal hormone therapy and breast cancer risk: a population-based cohort study of 1.3 million women in Norway. Br J Cancer. 131(1): 126-137. https://doi.org/10.1038/s41416-024-02590-1 PMID: 38740969
  89. Thakral A, Lee JJ, Hou T, Hueniken K, Dudding T, Gormley M, et al. (2024). Smoking and alcohol by HPV status in head and neck cancer: a Mendelian randomization study. Nat Commun. 15(1): 7835. https://doi.org/10.1038/s41467-024-51679-x PMID: 39244563
  90. Trias-Llimos S, Renteria E, Rutigliano R, Aggarwal A, Moodley J, Unger-Saldana K, et al. (2024). Deciphering the sex gap in global life expectancy: the impact of female-specific cancers 1990-2019. J Natl Cancer Inst. 116(12): 1934-1941. https://doi.org/10.1093/jnci/djae191 PMID: 39141445
  91. Vaccarella S, Li M, Bray F, Kvale R, Serraino D, Lorenzoni V, et al. (2024). Prostate cancer incidence and mortality in Europe and implications for screening activities: population based study. BMJ. 386: e077738. https://doi.org/10.1136/bmj-2023-077738 PMID: 39231588
  92. Wang S, Zheng R, Li J, Zeng H, Li L, Chen R, et al. (2024). Global, regional, and national lifetime risks of developing and dying from gastrointestinal cancers in 185 countries: a population-based systematic analysis of GLOBOCAN. Lancet Gastroenterol Hepatol. 9(3): 229-237. https://doi.org/10.1016/S2468-1253(23)00366-7 PMID: 38185129
  93. Weber A, Vignat J, Shah R, Morgan E, Laversanne M, Nagy P, et al. (2024). Global burden of bladder cancer mortality in 2020 and 2040 according to GLOBOCAN estimates. World J Urol. 42(1): 237. https://doi.org/10.1007/s00345-024-04949-8 PMID: 38625417
  94. Yang SL, Togawa K, Gilmour S, Leon ME, Soerjomataram I, Katanoda K (2024). Projecting the impact of implementation of WHO MPOWER measures on smoking prevalence and mortality in Japan. Tob Control. 33(3): 295-301. https://doi.org/10.1136/tc-2022-057262 PMID: 36100264
  95. Zahed H, Feng X, Sheikh M, Bray F, Ferlay J, Ginsburg O, et al. (2024). Age at diagnosis for lung, colon, breast and prostate cancers: An international comparative study. Int J Cancer. 154(1): 28-40. https://doi.org/10.1002/ijc.34671 PMID: 37615573
  96. Znaor A, Eser S, Bendahhou K, Shelpai W, Al Lawati N, A EL, et al. (2024). Stage at diagnosis of colorectal cancer in the Middle East and Northern Africa: A population-based cancer registry study. Int J Cancer. 155(1): 54-60. https://doi.org/10.1002/ijc.34895 PMID: 38456478
  97. Ali M, Nusselder W, Weiderpass E, Corbex M, Bray F, Vaccarella S (2023). Inequities in cancer outcomes. Bull World Health Organ. 101(9): 550. https://doi.org/10.2471/BLT.23.290661 PMID: 37663873
  98. Banham D, Roder D, Thompson S, Williamson A, Bray F, Currow D (2023). The effect of general practice contact on cancer stage at diagnosis in Aboriginal and non-Aboriginal residents of New South Wales. Cancer Causes Control. 34(10): 909-926. https://doi.org/10.1007/s10552-023-01727-6 PMID: 37329444
  99. Barchuk A, Tursun-Zade R, Nazarova E, Komarov Y, Tyurina E, Tumanova Y, et al. (2023). Completeness of regional cancer registry data in Northwest Russia 2008-2017. BMC Cancer. 23(1): 994. https://doi.org/10.1186/s12885-023-11492-z PMID: 37853404
  100. Bauer M, Vetter M, Stuckrath K, Yohannes M, Desalegn Z, Yalew T, et al. (2023). Regional Variation in the Tumor Microenvironment, Immune Escape and Prognostic Factors in Breast Cancer in Sub-Saharan Africa. Cancer Immunol Res. 11(6): 720-731. https://doi.org/10.1158/2326-6066.CIR-22-0795 PMID: 37058582
  101. Bergengren O, Pekala KR, Matsoukas K, Fainberg J, Mungovan SF, Bratt O, et al. (2023). 2022 Update on Prostate Cancer Epidemiology and Risk Factors-A Systematic Review. Eur Urol. 84(2): 191-206. https://doi.org/10.1016/j.eururo.2023.04.021 PMID: 37202314
  102. Blanco-Lopez J, Iguacel I, Pisanu S, Almeida CCB, Steliarova-Foucher E, Sierens C, et al. (2023). Role of Maternal Diet in the Risk of Childhood Acute Leukemia: A Systematic Review and Meta-Analysis. Int J Environ Res Public Health. 20(7): 5428. https://doi.org/10.3390/ijerph20075428 PMID: 37048042
  103. Budhathoki S, Diergaarde B, Liu G, Olshan A, Ness A, Waterboer T, et al. (2023). A risk prediction model for head and neck cancers incorporating lifestyle factors, HPV serology and genetic markers. Int J Cancer. 152(10): 2069-2080. https://doi.org/10.1002/ijc.34444 PMID: 36694401
  104. Cabasag CJ, Arnold M, Rutherford M, Ferlay J, Bardot A, Morgan E, et al. (2023). Shifting incidence and survival of epithelial ovarian cancer (1995-2014): A SurvMark-2 study. Int J Cancer. 152(9): 1763-1777. https://doi.org/10.1002/ijc.34403 PMID: 36533660
  105. Chen JG, Chen HZ, Zhu J, Shen AG, Sun XY, Parkin DM (2023). Cancer survival: left truncation and comparison of results from hospital-based cancer registry and population-based cancer registry. Front Oncol. 13: 1173828. https://doi.org/10.3389/fonc.2023.1173828 PMID: 37350938
  106. De Camargo Cancela M, Monteiro Dos Santos JE, Lopes de Souza LB, Martins LFL, Bezerra de Souza DL, Barchuk A, et al. (2023). The economic impact of cancer mortality among working-age individuals in Brazil from 2001 to 2030. Cancer Epidemiol. 86: 102438. https://doi.org/10.1016/j.canep.2023.102438 PMID: 37579673
  107. Deshmukh AA, Damgacioglu H, Georges D, Sonawane K, Ferlay J, Bray F, et al. (2023). Global burden of HPV-attributable squamous cell carcinoma of the anus in 2020, according to sex and HIV status: A worldwide analysis. Int J Cancer. 152(3): 417-428. https://doi.org/10.1002/ijc.34269 PMID: 36054026
  108. Frick C, Rumgay H, Vignat J, Ginsburg O, Nolte E, Bray F, et al. (2023). Quantitative estimates of preventable and treatable deaths from 36 cancers worldwide: a population-based study. Lancet Glob Health. 11(11): e1700-e1712. https://doi.org/10.1016/S2214-109X(23)00406-0 PMID: 37774721
  109. Ghasemi-Kebria F, Jafari-Delouie N, Semnani S, Fazel A, Etemadi A, Norouzi A, et al. (2023). Colorectal cancer incidence trends in Golestan, Iran: An age-period-cohort analysis 2004-2018. Cancer Epidemiol. 86: 102415. https://doi.org/10.1016/j.canep.2023.102415 PMID: 37442047
  110. Ghasemi-Kebria F, Semnani S, Fazel A, Etemadi A, Amiriani T, Naeimi-Tabiei M, et al. (2023). Esophageal and gastric cancer incidence trends in Golestan, Iran: An age-period-cohort analysis 2004 to 2018. Int J Cancer. 153(1): 73-82. https://doi.org/10.1002/ijc.34518 PMID: 36943026
  111. Gini A, Colombet M, de Paula Silva N, Visser O, Youlden D, Soerjomataram I, et al. (2023). A new method of estimating prevalence of childhood cancer survivors (POCCS): example of the 20-year prevalence in The Netherlands. Int J Epidemiol. 52(6): 1898-1906. https://doi.org/10.1093/ije/dyad124 PMID: 37738448
  112. Ginsburg O, Vanderpuye V, Beddoe AM, Bhoo-Pathy N, Bray F, Caduff C, et al. (2023). Women, power, and cancer: a Lancet Commission. Lancet. 402(10417): 2113-2166. https://doi.org/10.1016/S0140-6736(23)01701-4 PMID: 37774725
  113. Gizaw M, Parkin DM, Stoter O, Korir A, Kamate B, Liu B, et al. (2023). Trends in the incidence of ovarian cancer in sub-Saharan Africa. Int J Cancer. 152(7): 1328-1336. https://doi.org/10.1002/ijc.34335 PMID: 36274630
  114. Guimaraes Ribeiro A, Ferlay J, Piñeros M, Dias de Oliveira Latorre MdR, Tavares Guerreiro Fregnani JH, Bray F (2023). Geographic variations in cancer incidence and mortality in the State of São Paulo, Brazil 2001–17. Cancer Epidemiol. 85: 102403. https://doi.org/10.1016/j.canep.2023.102403 PMID: 37390700
  115. Hammerl L, Mezger NCS, Seraphin TP, Joko-Fru WY, Griesel M, Feuchtner J, et al. (2023). Treatment and Survival Among Patients With Colorectal Cancer in Sub-Saharan Africa: A Multicentric Population-Based Follow-Up Study. J Natl Compr Canc Netw. 21(9): 924-933 e927. https://doi.org/10.6004/jnccn.2023.7041 PMID: 37673109
  116. Hanly P, Ortega MO, Pearce A, Cancela MD, Soerjomataram I, Sharp L (2023). Estimating Global Friction Periods for Economic Evaluation: A Case Study of Selected OECD Member Countries. Pharmacoeconomics. 41(9): 1093-1101. https://doi.org/10.1007/s40273-023-01261-y PMID: 37036642
  117. Jubber I, Ong S, Bukavina L, Black PC, Comperat E, Kamat AM, et al. (2023). Epidemiology of Bladder Cancer in 2023: A Systematic Review of Risk Factors. Eur Urol. 84(2): 176-190. https://doi.org/10.1016/j.eururo.2023.03.029 PMID: 37198015
  118. Kidayi PL, Pakpour AH, Saboonchi F, Bray F, Manhica H, Mtuya CC, et al. (2023). Cross-Cultural Adaptation and Psychometric Properties of the Swahili Version of the European Organization for Research and Treatment of Cancer (EORTC) QLQ-BR45 among Breast Cancer Patients in Tanzania. Healthcare. 11(18): 15. https://doi.org/10.3390/healthcare11182467 PMID: 37761665
  119. Kiss Z, Kocsis J, Nikolenyi A, Horvath Z, Knollmajer K, Benedek A, et al. (2023). Opposite trends in incidence of breast cancer in young and old female cohorts in Hungary and the impact of the Covid-19 pandemic: a nationwide study between 2011-2020. Front Oncol. 13: 1182170. https://doi.org/10.3389/fonc.2023.1182170 PMID: 37795445
  120. Laronningen S, Skog A, Engholm G, Ferlay J, Johannesen TB, Kristiansen MF, et al. (2023). Nordcan.R: a new tool for federated analysis and quality assurance of cancer registry data. Front Oncol. 13: 1098342. https://doi.org/10.3389/fonc.2023.1098342 PMID: 37614501
  121. Li M, Meheus F, Polazzi S, Delafosse P, Borson-Chazot F, Seigneurin A, et al. (2023). The Economic Cost of Thyroid Cancer in France and the Corresponding Share Associated With Treatment of Overdiagnosed Cases. Value Health. 26(8): 1175-1182. https://doi.org/10.1016/j.jval.2023.02.016 PMID: 36921898
  122. Li M, Park JY, Sheikh M, Kayamba V, Rumgay H, Jenab M, et al. (2023). Population-based investigation of common and deviating patterns of gastric cancer and oesophageal cancer incidence across populations and time. Gut. 72(5): 846-854. https://doi.org/10.1136/gutjnl-2022-328233 PMID: 36241389
  123. Liu B, Abraham N, Chitsike I, Sylvie CGL, Kambugu J, Stevy NMA, et al. (2023). Enhancing information on stage at diagnosis for childhood cancer in Africa. Pediatr Blood Cancer. 70(10): e30555. https://doi.org/10.1002/pbc.30555 PMID: 37432023
  124. Luo G, Zhang Y, Etxeberria J, Arnold M, Cai X, Hao Y, et al. (2023). Projections of Lung Cancer Incidence by 2035 in 40 Countries Worldwide: Population-Based Study. JMIR Public Health Surveill. 9(1): e43651. https://doi.org/10.2196/43651 PMID: 36800235
  125. Macciotta A, Catalano A, Giraudo MT, Weiderpass E, Ferrari P, Freisling H, et al. (2023). Mediating Role of Lifestyle Behaviors in the Association between Education and Cancer: Results from the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev. 32(1): 132-140. https://doi.org/10.1158/1055-9965.EPI-22-0777 PMID: 36306379
  126. Mafra A, Bardot A, Charvat H, Weiderpass E, Soerjomataram I, Fregnani J (2023). Cancer survival in the northwestern of Sao Paulo State, Brazil: A population-based study. Cancer Epidemiol. 83: 102339. https://doi.org/10.1016/j.canep.2023.102339 PMID: 36863216
  127. Mallon B, Kabore R, Couitchere L, Akonde FB, Narison MLR, Budiongo A, et al. (2023). The feasibility of implementing Toronto childhood cancer stage guidelines and estimating the impact on outcome for childhood cancers in seven pediatric oncology units in sub-Saharan Africa. A study from the Franco-African Pediatric Oncology Group. Pediatr Blood Cancer. 70(12): e30664. https://doi.org/10.1002/pbc.30664 PMID: 37732944
  128. Marant Micallef C, Charvat H, Houot MT, Vignat J, Straif K, Paul A, et al. (2023). Estimated number of cancers attributable to occupational exposures in France in 2017: an update using a new method for improved estimates. J Expo Sci Environ Epidemiol. 33(1): 125-131. https://doi.org/10.1038/s41370-021-00353-1 PMID: 34172838
  129. Mohar A, Paredes A, Brau-Figueroa H, Sanchez A, Palafox A, Rivera-Gomez R, et al. (2023). [Not Available]. Salud Publica Mex. 66(1, ene-feb): 104-112. https://doi.org/10.21149/15258 PMID: 38065103
  130. Morgan E, Arnold M, Gini A, Lorenzoni V, Cabasag CJ, Laversanne M, et al. (2023). Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut. 72(2): 338-344. https://doi.org/10.1136/gutjnl-2022-327736 PMID: 36604116
  131. Morgan E, O’Neill C, Bardot A, Walsh P, Soerjomataram I, Arnold M (2023). The Challenges of Collecting Long-Term Outcomes in Cancer Patients on the Population-Level: The Case of Metastatic Breast Cancer. J Registry Manag. 50(4): 173-175. PMID: 38504704
  132. Myklebust TA, Aagnes B, Nilssen Y, Rutherford M, Lambert PC, Andersson TML, et al. (2023). Improving communication of cancer survival statistics-feasibility of implementing model-based algorithms in routine publications. Br J Cancer. 129(5): 819-828. https://doi.org/10.1038/s41416-023-02360-5 PMID: 37433898
  133. Ortega-Ortega M, Hanly P, Pearce A, Soerjomataram I, Sharp L (2023). Projected Impact on Labour Productivity Costs of Cancer-Related Premature Mortality in Europe 2018-2040. Appl Health Econ Health Policy. 21(6): 877-889. https://doi.org/10.1007/s40258-023-00824-6 PMID: 37552416
  134. Parkin DM, Liu B, Adoubi I, Makouanzi AS, Masalu N, Mrema C, et al. (2023). Enhancing information on stage at diagnosis of cancer in Africa. Acta Oncol. 62(4): 335-341. https://doi.org/10.1080/0284186X.2023.2205548 PMID: 37102435
  135. Pineros M, Brierley J, Barrios E, Cueva P, Musetti C, Pardo C, et al. (2023). Accuracy of Essential TNM to stage large colorectal (T3/T4) cancers in absence of nodal status information. Acta Oncol. 62(12): 1669-1671. https://doi.org/10.1080/0284186X.2023.2257376 PMID: 37738263
  136. Ribeiro AG, Ferlay J, Vaccarella S, Latorre M, Fregnani J, Bray F (2023). Thyroid Cancer Incidence and Mortality by Socioeconomic Level in the State of São Paulo, Brazil 2001-2017. Endocr Pract. 29(10): 770-778. https://doi.org/10.1016/j.eprac.2023.07.028 PMID: 37536501
  137. Ribeiro AG, Ferlay J, Vaccarella S, Latorre M, Fregnani J, Bray F (2023). Cancer inequalities in incidence and mortality in the State of Sao Paulo, Brazil 2001-17. Cancer Med. 12(15): 16615-16625. https://doi.org/10.1002/cam4.6259 PMID: 37345901
  138. Ritter J, Allen S, Cohen PD, Fajardo AF, Marx K, Loggetto P, et al. (2023). Financial hardship in families of children or adolescents with cancer: a systematic literature review. Lancet Oncol. 24(9): e364-e375. https://doi.org/10.1016/S1470-2045(23)00320-0 PMID: 37657477
  139. Roshandel G, Badar F, Barchuk A, Roder DM, Sangrajrang S, Mery L, et al. (2023). REPCAN: Guideline for REporting Population-based CANcer Registry Data. Asian Pac J Cancer Prev. 24(9): 3297-3303. https://doi.org/10.31557/APJCP.2023.24.9.3297 PMID: 37777857
  140. Rumgay H, Cabasag CJ, Offman J, de Camargo Cancela M, Barchuk A, Mathur P, et al. (2023). International burden of cancer deaths and years of life lost from cancer attributable to four major risk factors: a population-based study in Brazil, Russia, India, China, South Africa, the United Kingdom, and United States. EClinicalMedicine. 66: 102289. https://doi.org/10.1016/j.eclinm.2023.102289 PMID: 38192589
  141. Rumgay H, Ortega-Ortega M, Sharp L, Lunet N, Soerjomataram I (2023). The cost of premature death from cancer attributable to alcohol: Productivity losses in Europe in 2018. Cancer Epidemiol. 84: 102365. https://doi.org/10.1016/j.canep.2023.102365 PMID: 37058915
  142. Sawant P, Perera S, Jayanthi KGN, Ziyad AIA, Saoba S, Ervik M, et al. (2023). Application of Rupantaran software to Sri Lankan hospitals: an innovative tool developed to merge population-based cancer registry data into CanReg5. Ecancermedicalscience. 17: 1553. https://doi.org/10.3332/ecancer.2023.1553 PMID: 37377679
  143. Schmutz A, Matta M, Cairat M, Espina C, Schuz J, Kampman E, et al. (2023). Mapping the European cancer prevention research landscape: A case for more prevention research funding. Eur J Cancer. 195: 113378. https://doi.org/10.1016/j.ejca.2023.113378 PMID: 37924646
  144. Schuz J, Espina C, Carvalho A, Maza M, Luciani S, Cazap E, et al. (2023). Latin America and the Caribbean Code Against Cancer 1st Edition: A landmark for cancer prevention in the region. Cancer Epidemiol. 86 Suppl 1: 102453. https://doi.org/10.1016/j.canep.2023.102453 PMID: 37852730
  145. Schuz J, Ostroumova E, Kesminiene A, Davies L, Ahn HS, Togawa K, et al. (2023). Response to Toshihide Tsuda, Yumiko Miyano and Eiji Yamamoto [1]. Environ Health. 22(1): 13. https://doi.org/10.1186/s12940-022-00952-x PMID: 36703177
  146. Sedeta E, Sung H, Laversanne M, Bray F, Jemal A (2023). Recent Mortality Patterns and Time Trends for the Major Cancers in 47 Countries Worldwide. Cancer Epidemiol Biomarkers Prev. 32(7): 894-905. https://doi.org/10.1158/1055-9965.EPI-22-1133 PMID: 37195435
  147. Singh D, Vignat J, Lorenzoni V, Eslahi M, Ginsburg O, Lauby-Secretan B, et al. (2023). Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. Lancet Glob Health. 11(2): e197-e206. https://doi.org/10.1016/S2214-109X(22)00501-0 PMID: 36528031
  148. Soerjomataram I, Cabasag C, Bardot A, Fidler-Benaoudia MM, Miranda-Filho A, Ferlay J, et al. (2023). Cancer survival in Africa, central and south America, and Asia (SURVCAN-3): a population-based benchmarking study in 32 countries. Lancet Oncol. 24(1): 22-32. https://doi.org/10.1016/S1470-2045(22)00704-5 PMID: 36603919
  149. Song CV, van Gils CH, Yip CH, Soerjomataram I, Taib NAM, See MH, et al. (2023). Discriminatory Ability and Clinical Utility of the AJCC7 and AJCC8 Staging Systems for Breast Cancer in a Middle-Income Setting. Diagnostics (Basel). 13(4): 674. https://doi.org/10.3390/diagnostics13040674 PMID: 36832162
  150. Storm HH, Laronningen S, Bray F (2023). Do investments in cancer registry databases and tools bring added value? NORDCAN as an example. Acta Oncol. 62(6): 535-540. https://doi.org/10.1080/0284186X.2023.2218557 PMID: 37276272
  151. Vaccarella S, Georges D, Bray F, Ginsburg O, Charvat H, Martikainen P, et al. (2023). Socioeconomic inequalities in cancer mortality between and within countries in Europe: a population-based study. Lancet Reg Health Eur. 25: 100551. https://doi.org/10.1016/j.lanepe.2022.100551 PMID: 36818237
  152. Weber A, Laversanne M, Nagy P, Kenessey I, Soerjomataram I, Bray F (2023). Gains in life expectancy from decreasing cardiovascular disease and cancer mortality – an analysis of 28 European countries 1995-2019. Eur J Epidemiol. 38(11): 1141-1152. https://doi.org/10.1007/s10654-023-01039-8 PMID: 37676425
  153. Weber A, Mery L, Nagy P, Polgar C, Bray F, Kenessey I (2023). Evaluation of data quality at the Hungarian National Cancer Registry, 2000-2019. Cancer Epidemiol. 82: 102306. https://doi.org/10.1016/j.canep.2022.102306 PMID: 36521336
  154. Weber A, Morgan E, Vignat J, Laversanne M, Pizzato M, Rumgay H, et al. (2023). Lung cancer mortality in the wake of the changing smoking epidemic: a descriptive study of the global burden in 2020 and 2040. BMJ Open. 13(5): e065303. https://doi.org/10.1136/bmjopen-2022-065303 PMID: 37164477
  155. Wu L, Vaccarella S, Feng CY, Dal Maso L, Chen Y, Liu WW, et al. (2023). Mortality among papillary thyroid cancer patients by detection route: a hospital-based retrospective cohort study. Eur Thyroid J. 12(6): e230127. https://doi.org/10.1530/ETJ-23-0127 PMID: 37855414
  156. Xu J, Xu W, Choi J, Brhane Y, Christiani DC, Kothari J, et al. (2023). Large-scale whole exome sequencing studies identify two genes,CTSL and APOE, associated with lung cancer. PLoS Genet. 19(9): e1010902. https://doi.org/10.1371/journal.pgen.1010902 PMID: 37738239
  157. Youlden DR, Steliarova-Foucher E, Gini A, Silva NP, Aitken JFJ (2023). The growing prevalence of childhood cancer survivors in Australia. Pediatr Blood Cancer. 70(7): e30383. https://doi.org/10.1002/pbc.30383 PMID: 37092826
  158. Zhang Y, Rumgay H, Li M, Cao S, Chen W (2023). Nasopharyngeal Cancer Incidence and Mortality in 185 Countries in 2020 and the Projected Burden in 2040: Population-Based Global Epidemiological Profiling. JMIR Public Health Surveill. 9: e49968. https://doi.org/10.2196/49968 PMID: 37728964
  159. Zhang Y, Rumgay H, Li M, Yu H, Pan H, Ni J (2023). The global landscape of bladder cancer incidence and mortality in 2020 and projections to 2040. J Glob Health. 13: 04109. https://doi.org/10.7189/jogh.13.04109 PMID: 37712386
  160. Zhang Y, Vaccarella S, Morgan E, Li M, Etxeberria J, Chokunonga E, et al. (2023). Global variations in lung cancer incidence by histological subtype in 2020: a population-based study. Lancet Oncol. 24(11): 1206-1218. https://doi.org/10.1016/S1470-2045(23)00444-8 PMID: 37837979
  161. Zheng R, Wang S, Zhang S, Zeng H, Chen R, Sun K, et al. (2023). Global, regional, and national lifetime probabilities of developing cancer in 2020. Sci Bull (Beijing). 68(21): 2620-2628. https://doi.org/10.1016/j.scib.2023.09.041 PMID: 37821267
  162. Znaor A, Ryzhov A, Losada ML, Carvalho A, Smelov V, Barchuk A, et al. (2023). Breast and cervical cancer screening practices in nine countries of Eastern Europe and Central Asia: A population-based survey. J Cancer Policy. 38: 100436. https://doi.org/10.1016/j.jcpo.2023.100436 PMID: 37544479
  163. Zumsteg ZS, Luu M, Rosenberg PS, Elrod JK, Bray F, Vaccarella S, et al. (2023). Global epidemiologic patterns of oropharyngeal cancer incidence trends. J Natl Cancer Inst. 115(12): 1544-1554. https://doi.org/10.1093/jnci/djad169 PMID: 37603716
  164. Alkhalawi E, Znaor A, Al-Zahrani AS (2022). Quality of data from cancer registries in the Eastern Mediterranean region. Lancet Oncol. 23(4): 449-451. https://doi.org/10.1016/S1470-2045(22)00072-9 PMID: 35358450
  165. Andersson TM, Myklebust TA, Rutherford MJ, Moller B, Arnold M, Soerjomataram I, et al. (2022). Five ways to improve international comparisons of cancer survival: lessons learned from ICBP SURVMARK-2. Br J Cancer. 126(8): 1224-1228. https://doi.org/10.1038/s41416-022-01701-0 PMID: 35058590
  166. Andersson TM, Rutherford MJ, Myklebust TA, Moller B, Arnold M, Soerjomataram I, et al. (2022). A way to explore the existence of « immortals » in cancer registry data – An illustration using data from ICBP SURVMARK-2. Cancer Epidemiol. 76: 102085. https://doi.org/10.1016/j.canep.2021.102085 PMID: 34954495
  167. Araghi M, Fidler-Benaoudia M, Arnold M, Rutherford M, Bardot A, Ferlay J, et al. (2022). International differences in lung cancer survival by sex, histological type and stage at diagnosis: an ICBP SURVMARK-2 Study. Thorax. 77(4): 378-390. https://doi.org/10.1136/thoraxjnl-2020-216555 PMID: 34282033
  168. Arnold M, Morgan E, Bardot A, Rutherford MJ, Ferlay J, Little A, et al. (2022). International variation in oesophageal and gastric cancer survival 2012-2014: differences by histological subtype and stage at diagnosis (an ICBP SURVMARK-2 population-based study). Gut. 71(8): 1532-1543. https://doi.org/10.1136/gutjnl-2021-325266 PMID: 34824149
  169. Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, et al. (2022). Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast. 66: 15-23. https://doi.org/10.1016/j.breast.2022.08.010 PMID: 36084384
  170. Arnold M, Singh D, Laversanne M, Vignat J, Vaccarella S, Meheus F, et al. (2022). Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040. JAMA Dermatol. 158(5): 495-503. https://doi.org/10.1001/jamadermatol.2022.0160 PMID: 35353115
  171. Banack HR, Chang J, Stefanick ML, Arnold M, Anton-Culver H, Jiang L (2022). Relationship between BMI trajectories and cardiometabolic outcomes in postmenopausal women: a growth mixture modeling approach. Ann Epidemiol. 72: 9-17. https://doi.org/10.1016/j.annepidem.2022.04.004 PMID: 35469929
  172. Bravo LE, Garcia LS, Collazos P, Holguin J, Soerjomataram I, Miranda-Filho A (2022). Trends in long-term cancer survival in Cali, Colombia: 1998-2017. Colomb Med (Cali). 53(1): e2035082. https://doi.org/10.25100/cm.v53i1.5082 PMID: 36452118
  173. Bray F, Parkin DM, African Cancer Registry N (2022). Cancer in sub-Saharan Africa in 2020: a review of current estimates of the national burden, data gaps, and future needs. Lancet Oncol. 23(6): 719-728. https://doi.org/10.1016/S1470-2045(22)00270-4 PMID: 35550275
  174. Bukavina L, Bensalah K, Bray F, Carlo M, Challacombe B, Karam JA, et al. (2022). Epidemiology of Renal Cell Carcinoma: 2022 Update. Eur Urol. 82(5): 529-542. https://doi.org/10.1016/j.eururo.2022.08.019 PMID: 36100483
  175. Byrne J, Schmidtmann I, Rashid H, Hagberg O, Bagnasco F, Bardi E, et al. (2022). Impact of era of diagnosis on cause-specific late mortality among 77 423 five-year European survivors of childhood and adolescent cancer: The PanCareSurFup consortium. Int J Cancer. 150(3): 406-419. https://doi.org/10.1002/ijc.33817 PMID: 34551126
  176. Cabasag CJ, Arnold M, Rutherford M, Bardot A, Ferlay J, Morgan E, et al. (2022). Pancreatic cancer survival by stage and age in seven high-income countries (ICBP SURVMARK-2): a population-based study. Br J Cancer. 126(12): 1774-1782. https://doi.org/10.1038/s41416-022-01752-3 PMID: 35236937
  177. Cabasag CJ, Fagan PJ, Ferlay J, Vignat J, Laversanne M, Liu L, et al. (2022). Ovarian cancer today and tomorrow: A global assessment by world region and Human Development Index using GLOBOCAN 2020. Int J Cancer. 151(9): 1535-1541. https://doi.org/10.1002/ijc.34002 PMID: 35322413
  178. Cabasag CJ, Ferlay J, Laversanne M, Vignat J, Weber A, Soerjomataram I, et al. (2022). Pancreatic cancer: an increasing global public health concern. Gut. 71(8): 1686-1687. https://doi.org/10.1136/gutjnl-2021-326311 PMID: 34686577
  179. Cabasag CJ, Vignat J, Ferlay J, Arndt V, Lemmens V, Praagman J, et al. (2022). The preventability of cancer in Europe: A quantitative assessment of avoidable cancer cases across 17 cancer sites and 38 countries in 2020. Eur J Cancer. 177: 15-24. https://doi.org/10.1016/j.ejca.2022.09.030 PMID: 36323048
  180. Carle C, Hughes S, Freeman V, Campbell D, Egger S, Caruana M, et al. (2022). The risk of contracting SARS-CoV-2 or developing COVID-19 for people with cancer: A systematic review of the early evidence. J Cancer Policy. 33: 100338. https://doi.org/10.1016/j.jcpo.2022.100338 PMID: 35671919
  181. Chargari C, Arbyn M, Leary A, Abu-Rustum NR, Basu P, Bray F, et al. (2022). Increasing global accessibility to high-level treatments for cervical cancers. Gynecol Oncol. 164(1): 231-241. https://doi.org/10.1016/j.ygyno.2021.10.073 PMID: 34716024
  182. Charvat H, Freisling H, Noh H, Gaudet MM, Gunter MJ, Cross AJ, et al. (2022). Excess Body Fatness during Early to Mid-Adulthood and Survival from Colorectal and Breast Cancer: A Pooled Analysis of Five International Cohort Studies. Cancer Epidemiol Biomarkers Prev. 31(2): 325-333. https://doi.org/10.1158/1055-9965.EPI-21-0688 PMID: 34782393
  183. De Camargo Cancela M, Bezerra de Souza DL, Leite Martins LF, Borges L, Schilithz AO, Hanly P, et al. (2022). Can the sustainable development goals for cancer be met in Brazil? A population-based study. Front Oncol. 12: 1060608. https://doi.org/10.3389/fonc.2022.1060608 PMID: 36703792
  184. de Camargo Cancela M, de Oliveira Santos M, Migowski A, Pineros M (2022). Breast cancer among young women in Brazil: Differences between hospital and population-based series. Cancer Epidemiol. 79: 102193. https://doi.org/10.1016/j.canep.2022.102193 PMID: 35696767
  185. Dee EC, Eala MAB, Chua MLK, Bray F, Bhoo-Pathy N (2022). Adolescents and young adults with cancer: Considerations from the Southeast Asian perspective. Pediatr Blood Cancer. 69(7): e29593. https://doi.org/10.1002/pbc.29593 PMID: 35129873
  186. Dee EC, Santos PMG, Bray F (2022). The shifting epidemiology of lung cancer in Asian and Asian diaspora populations: Implications for clinical and global health policy research. Asia Pac J Clin Oncol. 18(5): e524-e525. https://doi.org/10.1111/ajco.13738 PMID: 35098661
  187. Doganis D, Karalexi MA, group N-Sc, Panagopoulou P, Bouka P, Bouka E, et al. (2022). Incidence patterns of childhood non-Wilms renal tumors: Comparing data of the Nationwide Registry of Childhood Hematological Malignancies and Solid Tumors (NARECHEM-ST), Greece, and the Surveillance, Epidemiology, and End Results Program (SEER), USA. Cancer Epidemiol. 78: 102153. https://doi.org/10.1016/j.canep.2022.102153 PMID: 35390585
  188. Freeman V, Hughes S, Carle C, Campbell D, Egger S, Hui H, et al. (2022). Are patients with cancer at higher risk of COVID-19-related death? A systematic review and critical appraisal of the early evidence. J Cancer Policy. 33: 100340. https://doi.org/10.1016/j.jcpo.2022.100340 PMID: 35680113
  189. Gil F, Miranda-Filho A, Uribe-Perez C, Arias-Ortiz NE, Yepez-Chamorro MC, Bravo LM, et al. (2022). Impact of the Management and Proportion of Lost to Follow-Up Cases on Cancer Survival Estimates for Small Population-Based Cancer Registries. J Cancer Epidemiol. 2022: 9068214. https://doi.org/10.1155/2022/9068214 PMID: 35140789
  190. Gini A, Selby K (2022). Fecal Immunochemical Tests: The Right Colorectal Cancer Screening Test for the Average-Risk Population? Clin Gastroenterol Hepatol. 20(10): 2216-2217. https://doi.org/10.1016/j.cgh.2022.03.030 PMID: 35390510
  191. Guida F, Kidman R, Ferlay J, Schuz J, Soerjomataram I, Kithaka B, et al. (2022). Global and regional estimates of orphans attributed to maternal cancer mortality in 2020. Nat Med. 28(12): 2563-2572. https://doi.org/10.1038/s41591-022-02109-2 PMID: 36404355
  192. Hanly P, Ortega-Ortega M, Soerjomataram I (2022). Cancer Premature Mortality Costs in Europe in 2020: A Comparison of the Human Capital Approach and the Friction Cost Approach. Curr Oncol. 29(5): 3552-3564. https://doi.org/10.3390/curroncol29050287 PMID: 35621677
  193. Ibrahim Khalil A, Franceschi S, de Martel C, Bray F, Clifford GM (2022). Burden of Kaposi sarcoma according to HIV status: A systematic review and global analysis. Int J Cancer. 150(12): 1948-1957. https://doi.org/10.1002/ijc.33951 PMID: 35085400
  194. Ibrahim Khalil A, Mpunga T, Wei F, Baussano I, de Martel C, Bray F, et al. (2022). Age-specific burden of cervical cancer associated with HIV: A global analysis with a focus on sub-Saharan Africa. Int J Cancer. 150(5): 761-772. https://doi.org/10.1002/ijc.33841 PMID: 34626498
  195. Ilbawi AM, Lam CG, Ortiz R, Bray F (2022). Investing in childhood cancer registries to drive progress. Lancet Child Adolesc Health. 6(7): 446-447. https://doi.org/10.1016/S2352-4642(22)00148-1 PMID: 35605627
  196. Kenessey I, Szoke G, Dobozi M, Szatmari I, Weber A, Fogarassy G, et al. (2022). Comparison of Cancer Survival Trends in Hungary in the Periods 2001-2005 and 2011-2015 According to a Population-Based Cancer Registry. Pathol Oncol Res. 28: 1610668. https://doi.org/10.3389/pore.2022.1610668 PMID: 36147657
  197. Kiss Z, Wittmann I, Polivka L, Surjan G, Surjan O, Barcza Z, et al. (2022). Nationwide Effectiveness of First and Second SARS-CoV2 Booster Vaccines During the Delta and Omicron Pandemic Waves in Hungary (HUN-VE 2 Study). Front Immunol. 13: 905585. https://doi.org/10.3389/fimmu.2022.905585 PMID: 35812442
  198. Kiss ZN, Bogos K, Tamasi L, Ostoros G, Muller V, Bittner N, et al. (2022). Underlying reasons for post-mortem diagnosed lung cancer cases – A robust retrospective comparative study from Hungary (HULC study). Front Oncol. 12: 1032366. https://doi.org/10.3389/fonc.2022.1032366 PMID: 36505881
  199. Kohls M, Freisling H, Charvat H, Soerjomataram I, Viallon V, Davila-Batista V, et al. (2022). Impact of cumulative body mass index and cardiometabolic diseases on survival among patients with colorectal and breast cancer: a multi-centre cohort study. BMC Cancer. 22(1): 546. https://doi.org/10.1186/s12885-022-09589-y PMID: 35568802
  200. Leal YA, Torres J, Gamboa R, Mantilla-Morales A, Pina-Sanchez P, Arrieta O, et al. (2022). Cancer Incidence in Merida, Mexico 2015-2018: First Report from the Population-based Cancer Registry. Arch Med Res. 53(8): 859-866. https://doi.org/10.1016/j.arcmed.2022.11.015 PMID: 36462950
  201. Li M, Zhang L, Charvat H, Callister ME, Sasieni P, Christodoulou E, et al. (2022). The influence of postscreening follow-up time and participant characteristics on estimates of overdiagnosis from lung cancer screening trials. Int J Cancer. 151(9): 1491-1501. https://doi.org/10.1002/ijc.34167 PMID: 35809038
  202. Lorenzoni V, Chaturvedi AK, Vignat J, Laversanne M, Bray F, Vaccarella S (2022). The Current Burden of Oropharyngeal Cancer: A Global Assessment Based on GLOBOCAN 2020. Cancer Epidemiol Biomarkers Prev. 31(11): 2054-2062. https://doi.org/10.1158/1055-9965.EPI-22-0642 PMID: 36173880
  203. Luo Q, Lew JB, Steinberg J, Worthington J, Yu XQ, Caruana M, et al. (2022). Trends in colon and rectal cancer mortality in Australia from 1972 to 2015 and associated projections to 2040. Sci Rep. 12(1): 3994. https://doi.org/10.1038/s41598-022-07797-x PMID: 35256697
  204. Luo Q, O’Connell DL, Yu XQ, Kahn C, Caruana M, Pesola F, et al. (2022). Cancer incidence and mortality in Australia from 2020 to 2044 and an exploratory analysis of the potential effect of treatment delays during the COVID-19 pandemic: a statistical modelling study. Lancet Public Health. 7(6): e537-e548. https://doi.org/10.1016/S2468-2667(22)00090-1 PMID: 35660215
  205. Mafra A, Laversanne M, Gospodarowicz M, Klinger P, De Paula Silva N, Pineros M, et al. (2022). Global patterns of non-Hodgkin lymphoma in 2020. Int J Cancer. 151(9): 1474-1481. https://doi.org/10.1002/ijc.34163 PMID: 35695282
  206. Mafra da Costa A, Hernandes ICP, Weiderpass E, Soerjomataram I, Fregnani J (2022). Cancer Statistics over Time in Northwestern Sao Paulo State, Brazil: Incidence and Mortality. Cancer Epidemiol Biomarkers Prev. 31(4): 707-714. https://doi.org/10.1158/1055-9965.EPI-21-0842 PMID: 35131883
  207. Malakova K, Cabasag CJ, Bardot A, Sangrajrang S, Chitapanarux I, Sripan P, et al. (2022). Cancer survival in Thailand from 1997 to 2012: Assessing the impact of universal health coverage. J Cancer Policy. 34: 100353. https://doi.org/10.1016/j.jcpo.2022.100353 PMID: 36357312
  208. Morgan E, Arnold M, Camargo MC, Gini A, Kunzmann AT, Matsuda T, et al. (2022). The current and future incidence and mortality of gastric cancer in 185 countries, 2020-40: A population-based modelling study. EClinicalMedicine. 47: 101404. https://doi.org/10.1016/j.eclinm.2022.101404 PMID: 35497064
  209. Morgan E, Soerjomataram I, Rumgay H, Coleman HG, Thrift AP, Vignat J, et al. (2022). The Global Landscape of Esophageal Squamous Cell Carcinoma and Esophageal Adenocarcinoma Incidence and Mortality in 2020 and Projections to 2040: New Estimates From GLOBOCAN 2020. Gastroenterology. 163(3): 649-658 e642. https://doi.org/10.1053/j.gastro.2022.05.054 PMID: 35671803
  210. Nemati S, Saeedi E, Lotfi F, Nahvijou A, Mohebbi E, Ravankhah Z, et al. (2022). National surveillance of cancer survival in Iran (IRANCANSURV): Analysis of data of 15 cancer sites from nine population-based cancer registries. Int J Cancer. 151(12): 2128-2135. https://doi.org/10.1002/ijc.34224 PMID: 35869869
  211. Nemati S, Saeedi E, Roshandel G, Nahvijou A, Badakhshan A, Akbari M, et al. (2022). Population-based cancer survival in the Golestan province in the northeastern part of Iran 2007-2012. Cancer Epidemiol. 77: 102089. https://doi.org/10.1016/j.canep.2021.102089 PMID: 35042146
  212. Noll F, Adams T, Cohen R, Soerjomataram I, Reid F (2022). Building opportunities to improve quality of life for women with ovarian cancer in low- and middle-income countries: the Every Woman Study. Int J Gynecol Cancer. 32(8): 1080-1081. https://doi.org/10.1136/ijgc-2022-003449 PMID: 35314459
  213. Ortega-Ortega M, Hanly P, Pearce A, Soerjomataram I, Sharp L (2022). Paid and unpaid productivity losses due to premature mortality from cancer in Europe in 2018. Int J Cancer. 150(4): 580-593. https://doi.org/10.1002/ijc.33826 PMID: 34569617
  214. Pastorino R, Sassano M, Danilo Tiziano F, Giraldi L, Amore R, Arzani D, et al. (2022). Plasma miR-151-3p as a Candidate Diagnostic Biomarker for Head and Neck Cancer: A Cross-sectional Study within the INHANCE Consortium. Cancer Epidemiol Biomarkers Prev. 31(12): 2237-2243. https://doi.org/10.1158/1055-9965.EPI-22-0376 PMID: 36126276
  215. Payne NWS, Brown KF, Delon C, Kotrotsios Y, Soerjomataram I, Shelton J (2022). Socio-economic deprivation and cancer incidence in England: Quantifying the role of smoking. PLoS One. 17(9): e0272202. https://doi.org/10.1371/journal.pone.0272202 PMID: 36129905
  216. Persson MSM, Yin W, Doring N, Risnes K, Weiderpass E, Steliarova-Foucher E, et al. (2022). Gestational age and cancer risk up to young adulthood in Swedish population born 1974 to 2013: A population-based cohort study. Int J Cancer. 150(8): 1269-1280. https://doi.org/10.1002/ijc.33886 PMID: 34855204
  217. Pierannunzio D, Fedeli U, Francisci S, Paoli A, Toffolutti F, Serraino D, et al. (2022). Thyroidectomies in Italy: A Population-Based National Analysis from 2001 to 2018. Thyroid. 32(3): 263-272. https://doi.org/10.1089/thy.2021.0531 PMID: 35018816
  218. Pilleron S, Alqurini N, Ferlay J, Haase KR, Hannan M, Janssen-Heijnen M, et al. (2022). International trends in cancer incidence in middle-aged and older adults in 44 countries. J Geriatr Oncol. 13(3): 346-355. https://doi.org/10.1016/j.jgo.2021.11.011 PMID: 34866023
  219. Pinello K, Baldassarre V, Steiger K, Paciello O, Pires I, Laufer-Amorim R, et al. (2022). Vet-ICD-O-Canine-1, a System for Coding Canine Neoplasms Based on the Human ICD-O-3.2. Cancers (Basel). 14(6). https://doi.org/10.3390/cancers14061529 PMID: 35326681
  220. Pineros M (2022). Evaluation and variability of quality in mortality statistics in Colombia: the importance of detail. Revista Colombiana De Cancerologia. 26(3): 241-243.
  221. Pineros M, Ginsburg O, Bendahhou K, Eser S, Shelpai WA, Fouad H, et al. (2022). Staging practices and breast cancer stage among population-based registries in the MENA region. Cancer Epidemiol. 81: 102250. https://doi.org/10.1016/j.canep.2022.102250 PMID: 36115143
  222. Pineros M, Laversanne M, Barrios E, Cancela MC, de Vries E, Pardo C, et al. (2022). An updated profile of the cancer burden, patterns and trends in Latin America and the Caribbean. Lancet Reg Health Am. 13: None. https://doi.org/10.1016/j.lana.2022.100294 PMID: 36189115
  223. Pizzato M, Li M, Vignat J, Laversanne M, Singh D, La Vecchia C, et al. (2022). The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020. Lancet Diabetes Endocrinol. 10(4): 264-272. https://doi.org/10.1016/S2213-8587(22)00035-3 PMID: 35271818
  224. Pizzato M, Martinsen JI, Heikkinen S, Vignat J, Lynge E, Sparen P, et al. (2022). Socioeconomic status and risk of lung cancer by histological subtype in the Nordic countries. Cancer Med. 11(8): 1850-1859. https://doi.org/10.1002/cam4.4548 PMID: 35166068
  225. Roel E, Pistillo A, Recalde M, Fernandez-Bertolin S, Aragon M, Soerjomataram I, et al. (2022). Cancer and the risk of coronavirus disease 2019 diagnosis, hospitalisation and death: A population-based multistate cohort study including 4 618 377 adults in Catalonia, Spain. Int J Cancer. 150(5): 782-794. https://doi.org/10.1002/ijc.33846 PMID: 34655476
  226. Rumgay H, Arnold M, Ferlay J, Lesi O, Cabasag CJ, Vignat J, et al. (2022). Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 77(6): 1598-1606. https://doi.org/10.1016/j.jhep.2022.08.021 PMID: 36208844
  227. Rumgay H, Ferlay J, de Martel C, Georges D, Ibrahim AS, Zheng R, et al. (2022). Global, regional and national burden of primary liver cancer by subtype. Eur J Cancer. 161: 108-118. https://doi.org/10.1016/j.ejca.2021.11.023 PMID: 34942552
  228. Sarich P, Cabasag CJ, Liebermann E, Vaneckova P, Carle C, Hughes S, et al. (2022). Tobacco smoking changes during the first pre-vaccination phases of the COVID-19 pandemic: A systematic review and meta-analysis. EClinicalMedicine. 47: 101375. https://doi.org/10.1016/j.eclinm.2022.101375 PMID: 35434579
  229. Singh D, Vaccarella S, Gini A, De Paula Silva N, Steliarova-Foucher E, Bray F (2022). Global patterns of Hodgkin lymphoma incidence and mortality in 2020 and a prediction of the future burden in 2040. Int J Cancer. 150(12): 1941-1947. https://doi.org/10.1002/ijc.33948 PMID: 35080783
  230. Smith L, Stiller CA, Aitken JF, Hjalgrim LL, Johannesen T, Lahteenmaki P, et al. (2022). International variation in childhood cancer mortality rates from 2001 to 2015: Comparison of trends in the International Cancer Benchmarking Partnership countries. Int J Cancer. 150(1): 28-37. https://doi.org/10.1002/ijc.33774 PMID: 34449879
  231. Soerjomataram I, Bardot A, Aitken J, Pineros M, Znaor A, Steliarova-Foucher E, et al. (2022). Impact of the COVID-19 pandemic on population-based cancer registry. Int J Cancer. 150(2): 273-278. https://doi.org/10.1002/ijc.33792 PMID: 34480348
  232. Soerjomataram I, Bray F, Lansdorp-Vogelaar I, Ginsburg O, Rahal R, Sullivan R, et al. (2022). COVID-19 and Cancer Global Modelling Consortium (CCGMC): A global reference to inform national recovery strategies. J Cancer Policy. 32: 100328. https://doi.org/10.1016/j.jcpo.2022.100328 PMID: 35560265
  233. Soo R, Mery L, Bardot A, Kanesvaran R, Keong TC, Pongnikorn D, et al. (2022). Diagnostic work-up and systemic treatment for advanced non-squamous non-small-cell lung cancer in four Southeast Asian countries. ESMO Open. 7(5): 100560. https://doi.org/10.1016/j.esmoop.2022.100560 PMID: 35988454
  234. Trapani D, Ginsburg O, Fadelu T, Lin NU, Hassett M, Ilbawi AM, et al. (2022). Global challenges and policy solutions in breast cancer control. Cancer Treat Rev. 104: 102339. https://doi.org/10.1016/j.ctrv.2022.102339 PMID: 35074727
  235. Voko Z, Kiss Z, Surjan G, Surjan O, Barcza Z, Wittmann I, et al. (2022). Effectiveness and Waning of Protection With Different SARS-CoV-2 Primary and Booster Vaccines During the Delta Pandemic Wave in 2021 in Hungary (HUN-VE 3 Study). Front Immunol. 13: 919408. https://doi.org/10.3389/fimmu.2022.919408 PMID: 35935993
  236. Wang S, Zheng R, Arnold M, Abnet C, Zeng H, Zhang S, et al. (2022). Global and national trends in the age-specific sex ratio of esophageal cancer and gastric cancer by subtype. Int J Cancer. 151(9): 1447-1461. https://doi.org/10.1002/ijc.34158 PMID: 35678331
  237. Weber A, Szatmari I, Dobozi M, Hilbert L, Branyiczkine Geczy G, Nagy P, et al. (2022). [Comparison of Hungarian Central Statistical Office’s causes of death data with the database of the Hungarian National Cancer Registry]. Orv Hetil. 163(37): 1481-1489. https://doi.org/10.1556/650.2022.32573 PMID: 36088625
  238. Withrow D, Pilleron S, Nikita N, Ferlay J, Sharma S, Nicholson B, et al. (2022). Current and projected number of years of life lost due to prostate cancer: A global study. Prostate. 82(11): 1088-1097. https://doi.org/10.1002/pros.24360 PMID: 35468227
  239. Yang SL, Togawa K, Gilmour S, Leon ME, Soerjomataram I, Katanoda K (2022). Projecting the impact of implementation of WHO MPOWER measures on smoking prevalence and mortality in Japan. Tob Control. https://doi.org/10.1136/tc-2022-057262 PMID: 36100264
  240. Znaor A, Corbex M, Cao B, Laversanne M, Ryzhov A, Smelov V, et al. (2022). Progress in reducing premature mortality from cancer and cardiovascular disease in the former Soviet Union, 2000-19. Eur J Public Health. 32(4): 624-629. https://doi.org/10.1093/eurpub/ckac030 PMID: 35441219
  241. Znaor A, Skakkebaek NE, Rajpert-De Meyts E, Kulis T, Laversanne M, Gurney J, et al. (2022). Global patterns in testicular cancer incidence and mortality in 2020. Int J Cancer. 151(5): 692-698. https://doi.org/10.1002/ijc.33999 PMID: 35277970



 
Visualisez les publications recentes

 

 

Surveillance du cancer
A propos Recherche Publications Sites internet associés Personnel
Fermer mode lecture
HAUT